Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAPTYSBIO, INCANAB · Entity 4640 | Director · President, CEO | March 12, 2026 | August 07, 2026 |
| First Tracks Biotherapeutics, Inc.TRAX · Entity 4696 | Director · President, CEO | August 15, 2026 | August 18, 2026 |
| Mirati Therapeutics, Inc.MRTX · Entity 94908 | EVP, Chief Operating Officer | February 02, 2021 | February 03, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAPTYSBIO, INC
Report date March 12, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 53,334 |
Reported balance
After 2026-03-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-12 · Grant · Acquired 53,334 · Balance 53,334 F1: Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on March 12, 2026. F2: Each PSU represents a conditional right to receive one share of the Issuer's Common Stock. F3: The PSUs vest and settle over two years; 50% vests on March 12 2027 and 50% vests on March 12, 2028, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on March 12, 2026.
F2: Each PSU represents a conditional right to receive one share of the Issuer's Common Stock.
F3: The PSUs vest and settle over two years; 50% vests on March 12 2027 and 50% vests on March 12, 2028, subject to the continuing service of the Reporting Person on each vesting date.
First Tracks Biotherapeutics, Inc.
Report date August 15, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 440,485 |
Reported balance
After 2026-08-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-15 · Grant · Acquired 193,575 · Balance 440,485 F1: Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on August 15, 2026. F2: Each PSU represents a conditional right to receive one share of the Issuer's Common Stock. F3: The PSUs vest and settle over two years; 50% vests on August 15, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on August 15, 2026.
F2: Each PSU represents a conditional right to receive one share of the Issuer's Common Stock.
F3: The PSUs vest and settle over two years; 50% vests on August 15, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date.
Mirati Therapeutics, Inc.
Report date February 02, 2021 · Filed February 03, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,638 |
Ending reported balance
After 2021-02-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-02-02 · Exercise / conversion · Acquired 1,340 · Balance 31,978 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Row 2 · 2021-02-02 · Sale · Disposed 1,340 · Balance 30,638 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. |
| Non Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $114.33 · Expires 2030-01-05 | Direct | 63,630 |
Reported balance
After 2021-02-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-02-02 · Exercise / conversion · Disposed 1,340 · Balance 63,630 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F2: 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.
F2: 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Spark Therapeutics, Inc.
Report date December 17, 2019 · Filed December 17, 2019
Section 16 reporting ended · disclosed 2019-12-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 1
1 source rowRow 1 · 2019-12-17 · Other · Disposed 38,828 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.73 · Expires 2029-01-15 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-12-17 · Disposition to issuer · Disposed 35,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.55 · Expires 2028-01-17 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-12-17 · Disposition to issuer · Disposed 26,250 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.17 · Expires 2027-01-17 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-12-17 · Disposition to issuer · Disposed 14,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.62 · Expires 2026-05-01 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-12-17 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-12-17 · Disposition to issuer · Disposed 21,500 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings). |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn.
F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 18, 2019 Filed Jan 23, 2019 22:14 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionRestricted Stock Units · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001609351-19-000023 · wf-form4_154828163322335.xml · derivative · entry 6 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock. F4 · derivative.exercise_date: On January 18, 2018, the reporting person was granted 10,000 restricted stock units that vest in four equal annual installments beginning January 18, 2019. Vested shares will be delivered to the reporting person annually on the vesting date. F4 · derivative.expiration_date: On January 18, 2018, the reporting person was granted 10,000 restricted stock units that vest in four equal annual installments beginning January 18, 2019. Vested shares will be delivered to the reporting person annually on the vesting date. Read SEC document |
| January 18, 2019 Filed Jan 23, 2019 22:14 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001609351-19-000023 · wf-form4_154828163322335.xml · derivative · entry 5 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock. F3 · derivative.exercise_date: On January 18, 2017, the reporting person was granted 8,000 restricted stock units that vest in four equal annual installments beginning January 18, 2018. Vested shares will be delivered to the reporting person annually on the vesting date. F3 · derivative.expiration_date: On January 18, 2017, the reporting person was granted 8,000 restricted stock units that vest in four equal annual installments beginning January 18, 2018. Vested shares will be delivered to the reporting person annually on the vesting date. Read SEC document |
| January 18, 2019 Filed Jan 23, 2019 22:14 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Tax withholdingCommon Stock | 823 | $45.08 | $37,100.84 |
DisclosureSEC source: 0001609351-19-000023 · wf-form4_154828163322335.xml · nonDerivative · entry 4 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,032 Read SEC document |
| January 18, 2019 Filed Jan 23, 2019 22:14 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 2,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001609351-19-000023 · wf-form4_154828163322335.xml · nonDerivative · entry 3 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,855 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converted into one share of Spark Therapeutics, Inc. common stock. Read SEC document |
| January 18, 2019 Filed Jan 23, 2019 22:14 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Tax withholdingCommon Stock | 766 | $45.08 | $34,531.28 |
DisclosureSEC source: 0001609351-19-000023 · wf-form4_154828163322335.xml · nonDerivative · entry 2 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,355 Read SEC document |
| January 18, 2019 Filed Jan 23, 2019 22:14 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 2,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001609351-19-000023 · wf-form4_154828163322335.xml · nonDerivative · entry 1 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converted into one share of Spark Therapeutics, Inc. common stock. Read SEC document |
| January 15, 2019 Filed Jan 18, 2019 02:36 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001609351-19-000009 · wf-form4_154777894440137.xml · derivative · entry 2 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 15, 2020. Vested shares will be delivered to the reporting person annually on the vesting date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 15, 2020. Vested shares will be delivered to the reporting person annually on the vesting date. Read SEC document |
| January 15, 2019 Filed Jan 18, 2019 02:36 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | GrantEmployee Stock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001609351-19-000009 · wf-form4_154777894440137.xml · derivative · entry 1 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-01-15 F1 · derivative.exercise_date: 25% vests January 15, 2020 and the remainder vests in equal annual installments over the following three years. Read SEC document |
| January 18, 2018 Filed Jan 23, 2018 00:04 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001609351-18-000011 · wf-form4_151666584891869.xml · derivative · entry 5 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutic common stock. F5 · derivative.exercise_date: On January 18, 2017, the reporting person was granted 8,000 restricted stock units that vest in four equal annual installments beginning January 18, 2018. Vested shares will be delivered to the reporting person annually on the vesting date. F5 · derivative.expiration_date: On January 18, 2017, the reporting person was granted 8,000 restricted stock units that vest in four equal annual installments beginning January 18, 2018. Vested shares will be delivered to the reporting person annually on the vesting date. Read SEC document |
| January 18, 2018 Filed Jan 23, 2018 00:04 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001609351-18-000011 · wf-form4_151666584891869.xml · derivative · entry 4 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutic common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 18, 2019. Vested shares will be delivered to the reporting person annually on the vesting date. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 18, 2019. Vested shares will be delivered to the reporting person annually on the vesting date. Read SEC document |
| January 18, 2018 Filed Jan 23, 2018 00:04 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | GrantEmployee Stock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $50.55 | $0.00 |
DisclosureSEC source: 0001609351-18-000011 · wf-form4_151666584891869.xml · derivative · entry 3 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2028-01-17 F2 · derivative.exercise_date: 25% vests January 18, 2019 and the remainder vests in equal annual installments over the following three years. Read SEC document |
| January 18, 2018 Filed Jan 23, 2018 00:04 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Tax withholdingCommon Stock | 879 | $50.55 | $44,433.45 |
DisclosureSEC source: 0001609351-18-000011 · wf-form4_151666584891869.xml · nonDerivative · entry 2 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,121 Read SEC document |
| January 18, 2018 Filed Jan 23, 2018 00:04 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 2,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001609351-18-000011 · wf-form4_151666584891869.xml · nonDerivative · entry 1 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converted into one share of Spark Therapeutics common stock. Read SEC document |
| October 24, 2017 Filed Oct 24, 2017 20:16 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $37.62 | $0.00 |
DisclosureSEC source: 0001609351-17-000109 · wf-form4_150887610057324.xml · derivative · entry 6 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 1,500 shares Expires 2026-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% vested May 2, 2017 and the remainder vests in equal quarterly installments over the following three years. Read SEC document |
| October 24, 2017 Filed Oct 24, 2017 20:16 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | SaleCommon Stock | 1,500 | $85.00 | $127,500.00 |
DisclosureSEC source: 0001609351-17-000109 · wf-form4_150887610057324.xml · nonDerivative · entry 4 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2017. Read SEC document |
| October 24, 2017 Filed Oct 24, 2017 20:16 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 1,500 | $37.62 | $56,430.00 |
DisclosureSEC source: 0001609351-17-000109 · wf-form4_150887610057324.xml · nonDerivative · entry 3 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 20, 2017 Filed Oct 24, 2017 20:16 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $37.62 | $0.00 |
DisclosureSEC source: 0001609351-17-000109 · wf-form4_150887610057324.xml · derivative · entry 5 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,500 Underlying: Common Stock · 6,000 shares Expires 2026-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% vested May 2, 2017 and the remainder vests in equal quarterly installments over the following three years. Read SEC document |
| October 20, 2017 Filed Oct 24, 2017 20:16 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | SaleCommon Stock | 6,000 | $79.95 | $479,700.00 |
DisclosureSEC source: 0001609351-17-000109 · wf-form4_150887610057324.xml · nonDerivative · entry 2 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.40 to $80.30, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| October 20, 2017 Filed Oct 24, 2017 20:16 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 6,000 | $37.62 | $225,720.00 |
DisclosureSEC source: 0001609351-17-000109 · wf-form4_150887610057324.xml · nonDerivative · entry 1 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 19, 2017 Filed Sep 20, 2017 20:27 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $37.62 | $0.00 |
DisclosureSEC source: 0001609351-17-000106 · wf-form4_150593921639753.xml · derivative · entry 3 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,500 Underlying: Common Stock · 1,500 shares Expires 2026-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% vested May 2, 2017 and the remainder vests in equal quarterly installments over the following three years. Read SEC document |
| September 19, 2017 Filed Sep 20, 2017 20:27 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | SaleCommon Stock | 1,500 | $85.00 | $127,500.00 |
DisclosureSEC source: 0001609351-17-000106 · wf-form4_150593921639753.xml · nonDerivative · entry 2 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2017. Read SEC document |
| September 19, 2017 Filed Sep 20, 2017 20:27 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 1,500 | $37.62 | $56,430.00 |
DisclosureSEC source: 0001609351-17-000106 · wf-form4_150593921639753.xml · nonDerivative · entry 1 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 12, 2017 Filed Sep 14, 2017 20:07 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $37.62 | $0.00 |
DisclosureSEC source: 0001609351-17-000104 · wf-form4_150541961216161.xml · derivative · entry 4 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,000 Underlying: Common Stock · 6,000 shares Expires 2026-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% vested May 2, 2017 and the remainder vests in equal quarterly installments over the following three years. Read SEC document |
| September 12, 2017 Filed Sep 14, 2017 20:07 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | SaleCommon Stock | 900 | $83.36 | $75,024.00 |
DisclosureSEC source: 0001609351-17-000104 · wf-form4_150541961216161.xml · nonDerivative · entry 3 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.27 to $83.73, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| September 12, 2017 Filed Sep 14, 2017 20:07 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | SaleCommon Stock | 5,100 | $82.35 | $419,985.00 |
DisclosureSEC source: 0001609351-17-000104 · wf-form4_150541961216161.xml · nonDerivative · entry 2 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.84 to $82.82, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| September 12, 2017 Filed Sep 14, 2017 20:07 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 6,000 | $37.62 | $225,720.00 |
DisclosureSEC source: 0001609351-17-000104 · wf-form4_150541961216161.xml · nonDerivative · entry 1 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 20:15 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $37.62 | $0.00 |
DisclosureSEC source: 0001609351-17-000102 · wf-form4_150516093442742.xml · derivative · entry 4 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 3,000 shares Expires 2026-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% vested May 2, 2017 and the remainder vests in equal quarterly installments over the following three years. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 20:15 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | SaleCommon Stock | 1,500 | $85.03 | $127,545.00 |
DisclosureSEC source: 0001609351-17-000102 · wf-form4_150516093442742.xml · nonDerivative · entry 3 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.04, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 20:15 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | SaleCommon Stock | 1,500 | $85.00 | $127,500.00 |
DisclosureSEC source: 0001609351-17-000102 · wf-form4_150516093442742.xml · nonDerivative · entry 2 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2017. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 20:15 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 3,000 | $37.62 | $112,860.00 |
DisclosureSEC source: 0001609351-17-000102 · wf-form4_150516093442742.xml · nonDerivative · entry 1 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 20:14 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $37.62 | $0.00 |
DisclosureSEC source: 0001609351-17-000081 · wf-form4_150110007491976.xml · derivative · entry 3 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,000 Underlying: Common Stock · 3,000 shares Expires 2026-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% vests May 2, 2017 and the remainder vests in equal quarterly installments over the following three years. Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 20:14 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | SaleCommon Stock | 3,000 | $70.00 | $210,000.00 |
DisclosureSEC source: 0001609351-17-000081 · wf-form4_150110007491976.xml · nonDerivative · entry 2 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2017. Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 20:14 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 3,000 | $37.62 | $112,860.00 |
DisclosureSEC source: 0001609351-17-000081 · wf-form4_150110007491976.xml · nonDerivative · entry 1 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2017 Filed Jun 29, 2017 20:29 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $37.62 | $0.00 |
DisclosureSEC source: 0001609351-17-000066 · wf-form4_149876815379601.xml · derivative · entry 3 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,000 Underlying: Common Stock · 4,500 shares Expires 2026-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% vests May 2, 2017 and the remainder vests in equal quarterly installments over the following three years. Read SEC document |
| June 29, 2017 Filed Jun 29, 2017 20:29 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | SaleCommon Stock | 4,500 | $62.71 | $282,195.00 |
DisclosureSEC source: 0001609351-17-000066 · wf-form4_149876815379601.xml · nonDerivative · entry 2 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.50 to $62.95, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| June 29, 2017 Filed Jun 29, 2017 20:29 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 4,500 | $37.62 | $169,290.00 |
DisclosureSEC source: 0001609351-17-000066 · wf-form4_149876815379601.xml · nonDerivative · entry 1 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2017 Filed May 17, 2017 20:36 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $37.62 | $0.00 |
DisclosureSEC source: 0001609351-17-000037 · wf-form4_149505338238575.xml · derivative · entry 3 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,500 Underlying: Common Stock · 4,500 shares Expires 2026-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% vests May 2, 2017 and the remainder vests in equal quarterly installments over the following three years. Read SEC document |
| May 15, 2017 Filed May 17, 2017 20:36 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | SaleCommon Stock | 4,500 | $56.90 | $256,050.00 |
DisclosureSEC source: 0001609351-17-000037 · wf-form4_149505338238575.xml · nonDerivative · entry 2 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2017. Read SEC document |
| May 15, 2017 Filed May 17, 2017 20:36 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 4,500 | $37.62 | $169,290.00 |
DisclosureSEC source: 0001609351-17-000037 · wf-form4_149505338238575.xml · nonDerivative · entry 1 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 21:06 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | GrantRestricted Stock Units · Derivative | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001609351-17-000012 · wf-form4_148494636102863.xml · derivative · entry 2 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 18, 2018. Vested shares will be delivered to the reporting person annually on the vesting date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 18, 2018. Vested shares will be delivered to the reporting person annually on the vesting date. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 21:06 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | GrantEmployee Stock Option (right to buy) · Derivative | 28,000 | $0.00 Strike: $56.17 | $0.00 |
DisclosureSEC source: 0001609351-17-000012 · wf-form4_148494636102863.xml · derivative · entry 1 Faga Daniel · CIK 0001673528 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2027-01-17 F1 · derivative.exercise_date: 25% vests January 18, 2018 and the remainder vests in equal annual installments over the following three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.